Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (341-350 of 627) with videos related to

Pageof 63
Sort By:
JACC. Cardiovascular Interventions|February 24, 2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])Harvey D White, Deepak L Bhatt, C Michael Gibson, et al.
Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.
The Journal of Invasive Cardiology|November 11, 2003
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main resultsKenneth W Mahaffey, Bruce E Lewis, Nancy M Wildermann, et al.
Vascular Medicine (London, England)|July 25, 2019
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trialCharles W Hopley, Sarah Kavanagh, Manesh R Patel, et al.
Heart (British Cardiac Society)|June 5, 2026
Changes in the metabolome after treatment with canagliflozin in patients with type 2 diabetesCraig Peter Coorey, Owen Tang, Mengbo Li, et al.
The American Journal of Medicine|November 27, 2016
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial FibrillationPaul L Hess, Sunghee Kim, Gregg C Fonarow, et al.
American Heart Journal|May 22, 2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trialSergio Leonardi, Kenneth W Mahaffey, Harvey D White, et al.
NPJ Digital Medicine|June 28, 2022
Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP)Ashish Sarraju, Clark Seninger, Vijaya Parameswaran, et al.
Journal of the American College of Cardiology|February 15, 2020
Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery DiseaseAxel Haine, Sarah Kavanagh, Jeffrey S Berger, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialPatrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Pageof 63

Showing results (341-350 of 627) with videos related to

Sort By:
Pageof 63
JACC. Cardiovascular Interventions|February 24, 2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])Harvey D White, Deepak L Bhatt, C Michael Gibson, et al.
Diabetes, Obesity & Metabolism|June 19, 2024
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trialKathryn Cardoza, Amy Kang, Brendan Smyth, et al.
The Journal of Invasive Cardiology|November 11, 2003
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main resultsKenneth W Mahaffey, Bruce E Lewis, Nancy M Wildermann, et al.
Vascular Medicine (London, England)|July 25, 2019
Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trialCharles W Hopley, Sarah Kavanagh, Manesh R Patel, et al.
Heart (British Cardiac Society)|June 5, 2026
Changes in the metabolome after treatment with canagliflozin in patients with type 2 diabetesCraig Peter Coorey, Owen Tang, Mengbo Li, et al.
The American Journal of Medicine|November 27, 2016
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial FibrillationPaul L Hess, Sunghee Kim, Gregg C Fonarow, et al.
American Heart Journal|May 22, 2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trialSergio Leonardi, Kenneth W Mahaffey, Harvey D White, et al.
NPJ Digital Medicine|June 28, 2022
Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP)Ashish Sarraju, Clark Seninger, Vijaya Parameswaran, et al.
Journal of the American College of Cardiology|February 15, 2020
Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery DiseaseAxel Haine, Sarah Kavanagh, Jeffrey S Berger, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialPatrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Pageof 63